"We are pleased to see the use of AQUA(R) technology expanded within this preeminent cancer research center," said John L. Tonkinson, Ph.D., Vice President of Business Development at HistoRx. "We look forward to exciting new applications and results utilizing AQUA(R) technology coming out of the Dana-Farber/Harvard Cancer Center institutions."
About the HARP(TM) Program
The HistoRx Academic Research Program (HARP) provides oncologists and pathologists at leading academic research institutions in North America and Europe access to the AQUA(R) technology for use exclusively in noncommercial research. Academic and other not-for-profit research institutions are eligible to participate in HARP. Membership benefits include noncommercial use of the AQUA platform. (System components include AQUA(R) software for tissue analysis and the PM-2000(TM) image analyzer.)
About HistoRx (http://www.historx.com)
HistoRx is developing and commercializing pioneering quantitative
histopathology technology that provides exceptional measurement and
localization of protein biomarkers in their natural context within tissue.
The HistoRx proprietary AQUA(R) technology is the first platform capable of
measuring biomarker concentration with subcellular resolution to generate
more precise, efficient, and cost-effective answers about the safety and
effectiveness of new therapeutics in development as well as enable the
development of companion diagnostic tests for targeted therapies. HistoRx
services are used by pharmaceutical and biotechnology companies throughout
discovery research, preclinical studies, and clinical drug development.
HistoRx companion diagnostic products are linked to our partners' drug
candidates in development to predict therapeutic outcome. HistoRx also
pursues internal programs to develop proprietary in vitro diagnostics that
offer substantial improvements over ex
|SOURCE HistoRx, Inc.|
Copyright©2008 PR Newswire.
All rights reserved